Trabodenoson

Drug Profile

Trabodenoson

Alternative Names: INO-8875; PJ-875

Latest Information Update: 09 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Antiarrhythmics
  • Mechanism of Action Adenosine A1 receptor agonists; Gelatinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arrhythmias; Atrial fibrillation; Glaucoma; Ocular hypertension; Optic nerve disorders; Pain

Most Recent Events

  • 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
  • 31 Jul 2017 Discontinued - Phase-III for Glaucoma in USA (Ophthalmic) ,
  • 31 Jul 2017 Discontinued - Phase-III for Ocular hypertension in USA (Ophthalmic) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top